An Oral BTK Pill Cut Relapses in Two Phase Three MS Trials With Full Data Still Unreleased

An Oral BTK Pill Cut Relapses in Two Phase Three MS Trials With Full Data Still Unreleased

Novartis says remibrutinib beat teriflunomide on relapse rates in two Phase 3 MS trials, but has not released the underlying numbers.

Novartis Remibrutinib beats older MS drug in trials, boosts pipeline hopes

LONDON: Swiss drugmaker Novartis said on Tuesday its oral drug remibrutinib outperformed an older treatment in reducing relapses in patients with a form of multiple sclerosis, boosting hopes the medicine could become a blockbuster product.The trial results mark the first success from three closely watched Novartis pipeline programmes due to deliver data ⁠this year. Investors are focused on remibrutinib, heart drug pelacarsen and gene therapy del…

Novartis’ Remibrutinib Cuts Relapse Rates in Phase III Multiple Sclerosis Studies

In a recent press release, Novartis has reported positive topline results from its Phase III REMODEL-1 and REMODEL-2 trials, showing that the investigational oral Bruton’s tyrosine kinase (BTK) inhibitor remibrutinib significantly reduced disease activity in patients with relapsing multiple sclerosis (RMS) compared with teriflunomide. The twin studies met their primary endpoint, demonstrating a statistically significant […]

Novartis announces trial results for remibrutinib in relapsing multiple sclerosis

MS affects nearly three million people worldwide and has three main types